Dose of sugammadex in morbidly obese patients - a reply

Affiliations

Free article

Comment

T Loupec et al. Anaesthesia. 2016 Jun.

Free article

. 2016 Jun;71(6):731-2.

doi: 10.1111/anae.13499.

No abstract available

Comment on

A randomized, dose-finding, phase II study of the selective relaxant binding drug, Sugammadex, capable of safely reversing profound rocuronium-induced neuromuscular block.
Groudine SB, Soto R, Lien C, Drover D, Roberts K. Groudine SB, et al. Anesth Analg. 2007 Mar;104(3):555-62. doi: 10.1213/01.ane.0000260135.46070.c3. Anesth Analg. 2007. PMID: 17312208 Clinical Trial.
Reversal of profound rocuronium-induced blockade with sugammadex: a randomized comparison with neostigmine.
Jones RK, Caldwell JE, Brull SJ, Soto RG. Jones RK, et al. Anesthesiology. 2008 Nov;109(5):816-24. doi: 10.1097/ALN.0b013e31818a3fee. Anesthesiology. 2008. PMID: 18946293 Clinical Trial.
Appropriate dosing of sugammadex to reverse deep rocuronium-induced neuromuscular blockade in morbidly obese patients.
Loupec T, Frasca D, Rousseau N, Faure JP, Mimoz O, Debaene B. Loupec T, et al. Anaesthesia. 2016 Mar;71(3):265-72. doi: 10.1111/anae.13344. Epub 2015 Dec 19. Anaesthesia. 2016. PMID: 26685122 Clinical Trial.